口服双膦酸盐与绝经后女性肺癌发病风险
口服双膦酸盐使用者与从未使用者肺癌发病率无显著差异(aHR=0.91,95%CI 0.80-1.04,P=0.16),但在从不吸烟者中观察到负相关(HR=0.57,95%CI 0.39-0.84,P<0.01)。
要点
- 口服双膦酸盐整体未显著降低绝经后女性肺癌风险。
- 从不吸烟者中双膦酸盐使用与肺癌风险降低相关。
- 需更多研究确认双膦酸盐对肺癌的潜在保护作用。
核心结论
- 在绝经后女性大型前瞻性队列中,口服双膦酸盐使用与从不吸烟者肺癌风险显著降低相关,提示可能具有保护作用。
主要发现
- 平均随访13.3年,2511名女性诊断为肺癌。
- 口服双膦酸盐使用者与从未使用者肺癌发病率无差异(aHR=0.91,95%CI 0.80-1.04,P=0.16)。
- 从不吸烟者中,双膦酸盐使用与肺癌风险负相关(HR=0.57,95%CI 0.39-0.84,P<0.01)。
临床怎么用
- 不应基于此结果改变双膦酸盐用于骨质疏松的临床决策。
- 对从不吸烟的绝经后女性,双膦酸盐使用与较低肺癌风险相关,但需进一步验证。
局限性
- 研究为观察性队列,不能证明因果关系。
- 原文指出需额外研究确认发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bisphosphonates are common medications for the treatment of osteoporosis in older populations. Several studies, including the Women's Health Initiative (WHI), have found inverse associations of bisphosphonate use with risk of breast and endometrial cancer, but little is known about its association with other common malignancies. The objective of this study was to evaluate the association of bisphosphonate use on the incidence of lung cancer in the WHI. PATIENTS AND METHODS: The association between oral bisphosphonate use and lung cancer risk was examined in 151 432 postmenopausal women enrolled into the WHI in 1993-1998. At baseline and during follow-up, participants completed an inventory of regularly used medications including bisphosphonates. RESULTS: After a mean follow-up of 13.3 years, 2511 women were diagnosed with incident lung cancer. There was no evidence of a difference in lung cancer incidence between oral bisphosphonate users and never users (adjusted hazard ratio = 0.91; 95% confidence intervals, 0.80-1.04; P = 0.16). However, an inverse association was observed among those who were never smokers (hazard ratio = 0.57, 95% confidence interval, 0.39-0.84; P < 0.01). CONCLUSION: In this large prospective cohort of postmenopausal women, oral bisphosphonate use was associated with significantly lower lung cancer risk among never smokers, suggesting bisphosphonates may have a protective effect against lung cancer. Additional studies are needed to confirm our findings.
引用
- Tao MH, Chen S, Freudenheim JL, et al. Oral bisphosphonate use and lung cancer incidence among postmenopausal women. Ann Oncol. 2018. PMID: 29617712. doi:10.1093/annonc/mdy097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。